Opinion|Videos|March 19, 2025
Hidden Burden of AD
Author(s)Matthew Zirwas, M.D.
An expert discusses the burden of physical symptoms and the financial impact, including indirect costs, of atopic dermatitis (AD) on patients and their families.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Can you discuss the burden of physical symptoms as well as the financial burden (such as indirect costs incurred due to the impact of disease) of AD on patients and their families?
Advertisement
Related to this article
CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.
Five transcranial magnetic stimulation sessions in one day improved processing speed in adults with schizophrenia, which holds promise for future treatment possibilities, according to researcher Heather Burrell Ward, M.D.
Imaging has been associated with four of the five most prevalent low-value services among Medicare beneficiaries.
One of teledentistry's most valuable applications is triage — helping a patient understand whether a concern can wait for an appointment, requires prompt attention or warrants emergency medical care.
Low birth volume fuels rural healthcare obstetric closures, limiting women’s health access—see which hospitals are most at risk.
In both mice and human cells, a small molecule selectively blocked the activity of MAP4K4, a protein involved in several major biological pathways.
Steering claims away from 340B-eligible pharmacies is one option but also the most disruptive, said Jeff Dunn, Pharm.D., MBA, of NeosRx.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Texas A&M researchers discover promising therapy for fatty liver disease
2
Why consumers still can’t comparison shop for medication
3
The hidden costs of routine radiology and how they can be addressed
4
Jeff Dunn, Pharm.D., MBA, on 340B rebates vs. discounts — and transparency | PBMI 2026
5